300 related articles for article (PubMed ID: 23483513)
41. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
42. [The deleterious effect of certain surface active agents on the ocular surface].
Ravet O
Bull Soc Belge Ophtalmol; 2007; (304):145-9. PubMed ID: 17718239
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
[TBL] [Abstract][Full Text] [Related]
44. Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?
Lockington D; Macdonald EC; Stewart P; Young D; Caslake M; Ramaesh K
Eye (Lond); 2012 May; 26(5):734-41. PubMed ID: 22388593
[TBL] [Abstract][Full Text] [Related]
45. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.
Pisella PJ; Pouliquen P; Baudouin C
Br J Ophthalmol; 2002 Apr; 86(4):418-23. PubMed ID: 11914211
[TBL] [Abstract][Full Text] [Related]
47. [Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study].
Denis P;
J Fr Ophtalmol; 2016 Sep; 39(7):622-30. PubMed ID: 27567675
[TBL] [Abstract][Full Text] [Related]
48. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
[TBL] [Abstract][Full Text] [Related]
49. [Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
Chikama T; Araie M; Nishida T
Nippon Ganka Gakkai Zasshi; 2013 May; 117(5):419-26. PubMed ID: 23855234
[No Abstract] [Full Text] [Related]
50. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
Levrat F; Pisella PJ; Baudouin C
J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
[TBL] [Abstract][Full Text] [Related]
51. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension.
Holló G; Bozkurt B; Irkec M
Expert Opin Pharmacother; 2009 Aug; 10(12):2015-24. PubMed ID: 19618994
[TBL] [Abstract][Full Text] [Related]
52. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
[TBL] [Abstract][Full Text] [Related]
53. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study.
Boimer C; Birt CM
J Glaucoma; 2013 Dec; 22(9):730-5. PubMed ID: 23524856
[TBL] [Abstract][Full Text] [Related]
54. Preservatives in eyedrops: the good, the bad and the ugly.
Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
[TBL] [Abstract][Full Text] [Related]
55. [Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].
Pfennigsdorf S; Eschstruth P
Ophthalmologe; 2016 May; 113(5):409-15. PubMed ID: 26563361
[TBL] [Abstract][Full Text] [Related]
56. Ocular benzalkonium chloride exposure: problems and solutions.
Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
[TBL] [Abstract][Full Text] [Related]
57. Ocular symptoms and signs with preserved and preservative-free glaucoma medications.
Jaenen N; Baudouin C; Pouliquen P; Manni G; Figueiredo A; Zeyen T
Eur J Ophthalmol; 2007; 17(3):341-9. PubMed ID: 17534814
[TBL] [Abstract][Full Text] [Related]
58. Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines.
Andole S; Senthil S
Semin Ophthalmol; 2023 Feb; 38(2):158-166. PubMed ID: 35915557
[TBL] [Abstract][Full Text] [Related]
59. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.
Lusthaus JA; Goldberg I
Expert Opin Investig Drugs; 2016 Oct; 25(10):1201-8. PubMed ID: 27548834
[TBL] [Abstract][Full Text] [Related]
60. Ocular surface changes in glaucoma patients related to topical medications.
Kovačević S; Čanović S; Pavičić AD; Kolega MŠ; Bašić JK
Coll Antropol; 2015 Mar; 39(1):47-9. PubMed ID: 26040067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
